Gilead Sciences is donating about 607,000 vials of remdesivir in the US over the next six weeks, less than half of its worldwide donation of 1.5 million vials of the COVID-19 treatment, reported Bloomberg.
According to the Department of Health and Human Services, the quantity is enough to treat 78,000 hospitalized patients in the US.
Gilead said the company was not deciding the allocation of remdesivir and deferred questions on donation and distribution to the US government.
"Initial supply of remdesivir is likely to be constrained to an even greater degree than we had previously estimated," commented RBC analyst Brian Abrahams, saying he had been expecting 80% of Gilead's donation to be distributed in the US.
The news source said more than 300,000 eligible US patients will not have access to remdesivir through the end of July, with Abrahams suggesting that this issue, as well as "continued limited supply through almost the end of the year," could put pressure on state health departments.